Skip to main content

Language(s) Spoken

English; Gujarati

Joined Kelsey-Seybold

September 2020

Accepting New Patients?

Yes

Professional Background

Dr. Vipal Durkal earned his Bachelor of Science at The University of Texas at Austin in 2009. He earned his Doctor of Medicine in 2014 at the John P. and Kathrine G. McGovern Medical School at The University of Texas Health Science Center at Houston. He completed his residency at the Medical College of Wisconsin Affiliated Hospitals in 2017 and his fellowship in Hematology and Oncology in 2020 at the University of California Los Angeles Medical Center. He joined Kelsey-Seybold in September 2020.

Professional Associations

Dr. Durkal is a member of the American Society of Clinical Oncology and the American Medical Association.

Hobbies and Interests

Dr. Durkal enjoys running, medical history, 20th century philosophy, cooking, community service, and spending time with family.

Fun Facts

The best advice Dr. Durkal has ever received is to “treat others how I would like to be treated.”

His most memorable trip was to Switzerland with his family in 2007. “I enjoy nature and hiking when I get the chance.”


​My philosophy of care is to treat not only the disease, but also the patient and their family. I strive to answer all questions and concerns the patient has regarding their illness. I work with an interdisciplinary team to achieve the best care possible.

​​​​​​​​​By Phone

Our Contact Center is here to serve you, 24 hours a day, 7 days a week.

713-442-1080​​
​​ ​


Awards & Recognitions


Research/Publications/Presentations

  • Durkal V, Nickols N, Rettig M. “A novel artificial intelligence biomarker: Validation of the automated bone scan index (aBSI) in veterans with metastatic prostate cancer.” ASCO 2020. 

  • Durkal V, Rettig, M. “Exceptions to the Rule: Using Pathology as a Gold Standard to Evaluate the Sensitivity of PSMA PET/CT Modality” ASCO 2019. 

  • Pattali S, Schmidt S, Durkal V, George, B. "Can Response to Treatment Predict Outcome in Patients with Metastatic Pancreatic Adenocarcinoma (MPAC)?" ASCO 2016. 

  • Schmidt S, Durkal V, George, B. Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and Gemcitabine + nab-paclitaxel (NabG). ASCO 2016. 

  • Schmidt, S, Durkal V, George B. Can the sequence of chemotherapy regimens influence outcome in patients with Metastatic Pancreatic Adenocarcinoma (MPAC)? ASCO 2016 

  • Durkal V, Ridolfi K. “An Aggressive Prostate Cancer Causing Dizziness.” Presented at Wisconsin State ACP Meeting. Proceedings of the 2015 Wisconsin Chapter of the American College of Physicians Meeting; 2015 Sep. 11-12; Wisconsin Dells, WI.

  • Svatek, Robert; Wilson, Clark; Durkal, Vipal; Culp, Stephen; Grossman, H. Barton; Kamat, Ashish; Dinney, Colin; Shah, Jay. “Location of Tumor in the Bladder Predicts Likelihood of Lymph Node Metastases at Radical Cystectomy and Disease Recurrence.” The Journal of Urology vol. 185 issue 4 April 2011. p. e741-e742. 

  • UT Houston Summer Research Program Fellow, Dept. of Renal Disease and Hypertension, The University of Texas Houston Medical School, Case-Control Study on Petrochemical Exposure and Nephrotoxicity in Gulf-Coast Workers, Primary Investigator: Donald Molony, M.D. Summer 2011.